Monica Marcus

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: SCIENCE ADVANCES. 2021;7(16):eabe6397

Rational antibody design for undruggable targets using kinetically controlled biomolecular probes.

Trkulja CL; Jungholm O; Davidson M; Jardemark K; Marcus MM; Hägglund J; Karlsson A; Karlsson R; Bruton J; Ivarsson N; Srinivasa SP; Cavallin A; Svensson P; Jeffries GDM; Christakopoulou M-N; Reymer A; Ashok A; Willman G; Papadia D; Johnsson E; Orwar O
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29(11):1282-1287

Enhancement of the antipsychotic effect of risperidone by sodium nitroprusside in rats.

Titulaer J; Malmerfelt A; Marcus MM; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2018;28(5):620-629

Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia.

Yamazaki M; Yamamoto N; Yarimizu J; Okabe M; Moriyama A; Furutani M; Marcus MM; Svensson TH; Harada K
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2017;27(4):411-417

The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism.

Björkholm C; Marcus MM; Konradsson-Geuken Å; Jardemark K; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2016;26(9):1401-1411

Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.

Marcus MM; Björkholm C; Malmerfelt A; Möller A; Påhlsson N; Konradsson-Geuken Å; Feltmann K; Jardemark K; Schilström B; Svensson TH
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2014;18(3):pyu068

Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat.

Björkholm C; Frånberg O; Malmerfelt A; Marcus MM; Konradsson-Geuken Å; Schilström B; Jardemark K; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2013;23(7):709-720

Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine.

Björkholm C; Jardemark K; Marcus MM; Malmerfelt A; Nyberg S; Schilström B; Svensson TH
Article: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY. 2012;39(1):143-148

Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat.

Johansson D; Falk A; Marcus MM; Svensson TH
Article: SYNAPSE. 2012;66(7):650-660

Involvement of 5-HT2A receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow.

Frånberg O; Marcus MM; Svensson TH
Article: PSYCHOPHARMACOLOGY. 2012;221(1):115-131

Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.

Jardemark K; Marcus MM; Malmerfelt A; Shahid M; Svensson TH
Article: SYNAPSE. 2012;66(4):277-290

Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electrophysiological evidence.

Marcus MM; Jardemark K; Malmerfelt A; Gertow J; Konradsson-Geuken A; Svensson TH
Article: SYNAPSE. 2011;65(5):357-367

Effects of S-citalopram, citalopram, and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N-methyl-D-aspartate receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat.

Schilström B; Konradsson-Geuken A; Ivanov V; Gertow J; Feltmann K; Marcus MM; Jardemark K; Svensson TH
Article: SYNAPSE. 2010;64(11):870-874

Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors.

Jardemark K; Marcus MM; Shahid M; Svensson TH
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2010;13(7):891-903

Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission.

Marcus MM; Wiker C; Frånberg O; Konradsson-Geuken A; Langlois X; Jardemark K; Svensson TH
Article: NEUROPSYCHOPHARMACOLOGY. 2010;35(9):1952-1961

Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission.

Marcus MM; Jardemark K; Malmerfelt A; Björkholm C; Svensson TH
Article: VACCINE. 2010;28(10):2161-2168

Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure.

de Villiers SHL; Lindblom N; Kalayanov G; Gordon S; Baraznenok I; Malmerfelt A; Marcus MM; Johansson AM; Svensson TH
Article: SYNAPSE. 2009;63(10):913-920

Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine.

Jardemark KE; Konradsson A; Schilström B; Marcus MM; Svensson TH
Article: PSYCHOPHARMACOLOGY. 2009;204(2):251-264

Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms.

Frånberg O; Marcus MM; Ivanov V; Schilström B; Shahid M; Svensson TH
Article: PSYCHOPHARMACOLOGY. 2008;196(3):417-429

Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

Frånberg O; Wiker C; Marcus MM; Konradsson A; Jardemark K; Schilström B; Shahid M; Wong EHF; Svensson TH
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 2007;573(1-3):148-160

Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsychotic potential.

Hertel P; Didriksen M; Pouzet B; Brennum LT; Søby KK; Larsen AK; Christoffersen CT; Ramirez T; Marcus MM; Svensson TH; Di Matteo V; Esposito E; Bang-Andersen B; Arnt J
Article: SYNAPSE. 2006;60(2):102-108

Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex.

Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2005;8(3):315-327

Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat.

Marcus MM; Jardemark KE; Wadenberg M-L; Langlois X; Hertel P; Svensson TH
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2005;8(2):157-162

The combination of nicotine with the D2 antagonist raclopride or the weak D4 antagonist L-745,870 generates a clozapine-like facilitation of NMDA receptor-mediated neurotransmission in pyramidal cells of the rat medial prefrontal cortex.

Jardemark K; Marcus MM; Konradsson A; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2002;12(5):379-386

Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses.

Marcus MM; Malmerfelt A; Nyberg S; Svensson TH
Article: NEUROPHARMACOLOGY. 2001;40(4):482-490

Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens.

Marcus MM; Mathé JM; Nomikos GG; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2000;10(5):355-363

Effects of antipsychotic drugs on cholecystokinin and preprotachykinin (substance P) mRNA expression in the rat hippocampal formation.

Zachrisson O; Nomikos GG; Marcus MM; Svensson TH; Lindefors N
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2000;10(4):245-253

Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism.

Marcus MM; Nomikos GG; Svensson TH
Article: ADVANCES IN PHARMACOLOGY. 1998;42:814-818

Interactions between catecholamines and serotonin: relevance to the pharmacology of schizophrenia.

Svensson TH; Mathé JM; Nomikos GG; Schilström B; Marcus M; Fagerquist M
Article: BRAIN RESEARCH. 1997;45(2):275-282

Effect of chronic antipsychotic drug treatment on preprosomatostatin and preprotachykinin A mRNA levels in the medial prefrontal cortex, the nucleus accumbens and the caudate putamen of the rat.

Marcus MM; Nomikos GG; Malmerfelt A; Zachrisson O; Lindefors N; Svensson TH
Article: JOURNAL OF NEURAL TRANSMISSION. 1997;104(1):1-10

Differential effects of acute and chronic nicotine on dopamine output in the core and shell of the rat nucleus accumbens.

Nisell M; Marcus M; Nomikos GG; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1996;6(1):29-38

Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens.

Marcus MM; Nomikos GG; Svensson TH
Article: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 1995;352(4):374-385

Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.

Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
Visa fler

Alla övriga publikationer

Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:S562-S563

Enhanced cortical dopaminergic and glutamatergic transmission and antipsychotic-like effect of risperidone by idazoxan

Marcus MM; Wiker C; Franberg O; Konradsson-Geuken A; Langlois X; Jardemark K; Svensson TH
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:S561

Reboxetine enhances cortical dopaminergic and glutamatergic transmission and the anti psychotic-like effect of olanzapine

Svensson TH; Jardemark K; Malmerfelt A; Bjorkholm C; Marcus MM
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S477

Asenapine:: preclinical evidence for clinical effects in schizophrenia and cognitive dysfunction

Svensson TH; Frånberg O; Konradsson A; Jardemark K; Schilstroem B; Wiker C; Ivanov V; Shahid M; Wong EHF; Marcus MM
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S33-S34

Adjuvant treatment with the anticonvulsant drug topiramate in schizophrenia

Konradsson A; Marcus MM; Sitzia R; Svensson TH; Jardemark KE
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S20-S21

Asenapine: preclinical evidence for clinical effects in Schizophrenia

Franberg O; Marcus MM; Konradsson A; Jardemark K; Schilstrom B; Wiker C; Shahid M; Wong EHF; Svensson TH
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2006;16:s30-s31

Inhibition of glycine uptake augments risperidone's effect on prefrontal glutamatergic transmission

Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2003;13:s301

Addition of nicotine to the D₂ antagonist raclopride or the weak D₄ antagonist L-745,870 augments NMDA-induced currents in pyramidal cells from the rat medial prefrontal cortex

Marcus MM; Jardemark KE; Konradsson Å; Svensson TH
Meeting abstract: SCHIZOPHRENIA RESEARCH. 1998;29(1-2):170

Effects of atypical antipsychotic drugs on dopamine output in the shell and the core of the nucleus accumbens:: Role of 5-HT_2A and α₁-adrenoceptor antagonism

Marcus MM; Nomikos GG; Svensson TH
Published conference paper: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1995;15(1 Suppl 1):11S-18S

Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected].

Svensson TH; Mathé JM; Andersson JL; Nomikos GG; Hildebrand BE; Marcus M

Anställningar

Anknuten till Forskning, Fysiologi och farmakologi, Karolinska Institutet, 2023-2025
Anknuten till Forskning, Fysiologi och farmakologi, Karolinska Institutet, 2023-2024

Examina och utbildning

MEDICINE DOKTORSEXAMEN, Institutionen för fysiologi och farmakologi, Karolinska Institutet, 2005
LICENTIATEXAMEN, Institutionen för fysiologi och farmakologi, Karolinska Institutet, 2002
Medicine Magisterexamen, Karolinska Institutet, 2002

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI